In the BioHarmony Drug Report Database

"Preview" Icon

Irinotecan

Camptosar, Onivyde, Onivyde pegylated (irinotecan) is a small molecule pharmaceutical. Irinotecan was first approved as Camptosar on 1996-06-14. It is used to treat breast neoplasms, colonic neoplasms, leukemia, lymphoma, and neoplasm metastasis amongst others in the USA. It has been approved in Europe to treat pancreatic neoplasms. The pharmaceutical is active against DNA topoisomerase 1. Camptosar’s patents are valid until 2036-10-15 (FDA).

 

Trade Name

 

Onivyde pegylated liposomal, known as Onivyde
 

Common Name

 

irinotecan
 

ChEMBL ID

 

CHEMBL481
 

Indication

 

breast neoplasms, colonic neoplasms, leukemia, lymphoma, neoplasm metastasis, non-small-cell lung carcinoma, pancreatic neoplasms, rectal neoplasms, stomach neoplasms
 

Drug Class

 

Antineoplastics (camptothecine derivatives)

Image (chem structure or protein)

Irinotecan structure rendering